ClinicalTrials.gg
Not yet recruitingNCT07604662ML-AKIUpdated May 22, 2026

Real-Time Acute Kidney Injury Perioperative Prediction Clinical Trial

An interventional study of EHR-Embedded AKI Risk Score and EHR-Embedded AKI Risk Score with Best Practice Advisory in Acute Kidney Injury, Surgery Complications and Anesthesia, sponsored by University of California, San Francisco. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-22.

Sponsored by University of California, San Francisco · Not applicable, Interventional, and Screening

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
25,518
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Acute Kidney Injury by University of California, San Francisco — 5 open to participants now, 6 under way, 1 of them phase 3. Acute Kidney Injury · University of California, San Francisco.

Planned enrollment
Largest of 10
25,518 · median 55
Started
2026
with 2 others
No phase
5 of 11
2 open now
Registered
10th of 11
by date

Among the 11 studies in Acute Kidney Injury by University of California, San Francisco, this one has the largest planned enrollment of the 10 interventional ones that give a count, is one of 3 that started in 2026, is one of 5 with no phase, and was the 10th registered.

Acute Kidney Injury

1,693 studies on the registry are indexed under Acute Kidney Injury; 392 are open to participants now.

Browse Acute Kidney Injury studies →

Open to participants now

5 of the 11 studies in Acute Kidney Injury by University of California, San Francisco are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 229 Acute Kidney Injury studies recruiting now, 161 (70%) set no upper age limit and 35 (15%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Acute Kidney Injury by University of California, San Francisco, or all of them as a file.
02

Study summary

This investigator-initiated, pragmatic trial evaluates whether displaying a machine learning (ML)- derived perioperative AKI risk score-alone or paired with an interruptive Best/Our Practice Advisory (BPA/OPA)-improves kidney-protective care and reduces kidney injury after non-obstetric surgery at UCSF. Approximately 75-100 attending anesthesiologists (clusters) are randomized 1:1:1 to: (a) Control (risk score hidden), (b) Score Only (visible preoperative AKI risk probability with passive KDIGO bundle recommendation), or (c) Score + BPA (visible risk plus interruptive KDIGO prompt for high-risk patients). CRNAs/residents follow their attending' s assignment. Adult inpatients (age ≥18) with expected overnight stay and eGFR ≥15 mL/min/1.73 m² are included; obstetrics, chronic dialysis, and kidney transplant patients are excluded. The underlying preoperative model was prospectively validated at UCSF and outperforms anesthesiologist risk estimation reported in the literature. The model was reviewed and approved by the AI Oversight Committee at UCSF. Primary endpoint is the continuous change in serum creatinine (mg/dL) from baseline to POD 1-2. Secondary outcomes include KDIGO-defined AKI, adherence to bundle elements (hemodynamics, balanced fluids, nephrotoxin avoidance, glycemic control), intraoperative hypotension time, fluid volumes, nephrotoxin exposure, perioperative hyperglycemia, length of stay, unplanned ICU transfer, readmission, dialysis, and in-hospital mortality. Data are obtained from the EHR; analysts are blinded. No direct subject interaction is planned; the investigators will request a waiver of patient consent. The study aims to demonstrate that ML-enabled, workflow-embedded decision support can safely and feasibly improve guideline concordant care and decrease early postoperative kidney injury.

03

Conditions studied

  • Acute Kidney Injury
  • Surgery Complications
  • Anesthesia

Browse trials for

Keywords

  • Acute Kidney Injury
  • Surgical Outcomes
  • Machine Learning
  • Clinical Decision Support
  • Electronic Health Records
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults ≥18 years undergoing non-obstetric surgery at UCSF.
  • Inpatient cases with expected overnight stay.
  • Baseline ≥15 mL/min/1.73 m².
  • Managed by an attending anesthesiologist randomized to one of three arms (CRNAs/residents follow attending).
  • Data available in the UCSF EHR for risk scoring and outcomes.

Exclusion criteria

Exclusion Criteria:

  • Obstetric procedures.
  • Chronic dialysis patients.
  • Kidney transplant recipients.
  • Cases without baseline creatinine/ or missing essential EHR elements needed for scoring/outcomes (operational exclusions).
  • Outpatient procedures without expected overnight stay.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
25,518 participants (estimated)

Study arms

  • No intervention
    Control Arm

    Participants receive usual perioperative care with a placeholder blank display without the machine learning-derived acute kidney injury (AKI) risk score. The clinical decision support tool remains hidden in the electronic health record, and no alerts or recommendations related to the study are shown.

  • Experimental
    Acute Kidney Injury Risk Score Only

    A machine learning-derived preoperative AKI risk score is displayed within the electronic health record for high-risk patients. A passive recommendation indicating that the patient may benefit from a KDIGO-based kidney-protective bundle is provided. The information is advisory only, and no interruptive alerts are used.

    Device: EHR-Embedded AKI Risk Score

  • Experimental
    Acute Kidney Injury Risk Score with Best Practice Advisory

    The machine learning-derived AKI risk score is displayed within the electronic health record for high-risk patients, accompanied by an interruptive Best Practice Advisory (BPA) that notifies providers that the patient may benefit from a KDIGO-based kidney-protective bundle. The alert is advisory only and does not mandate clinical actions.

    Device: EHR-Embedded AKI Risk Score with Best Practice Advisory

Interventions

  • DeviceEHR-Embedded AKI Risk Score

    A non-adaptive, machine learning-based clinical decision support tool integrated into the electronic health record that generates a preoperative probability of acute kidney injury (AKI) using routinely collected patient data. For patients identified as high risk, the tool displays the risk estimate to anesthesia providers without an accompanying Best Practice Advisory (BPA) recommending consideration of a KDIGO-based kidney-protective bundle. The intervention is advisory only, does not mandate clinical actions, and is designed to support provider decision-making within the existing clinical workflow.

    Also known as: EHR-Embedded AKI Clinical Decision Support Tool

  • DeviceEHR-Embedded AKI Risk Score with Best Practice Advisory

    A non-adaptive, machine learning-based clinical decision support tool integrated into the electronic health record that generates a preoperative probability of acute kidney injury (AKI) using routinely collected patient data. For patients identified as high risk, the tool displays the risk estimate to anesthesia providers with an accompanying Best Practice Advisory (BPA) recommending consideration of a KDIGO-based kidney-protective bundle. The intervention is advisory only, does not mandate clinical actions, and is designed to support provider decision-making within the existing clinical workflow.

    Also known as: EHR-Embedded AKI Clinical Decision Support Tool

06

What researchers measure

Primary outcomes

  1. Post-operative Change in Creatinine

    Maximum continuous change in serum creatinine (mg/dL) from baseline to post-operative day 1-2

    Time frame: From pre-operative baseline to 1-2 days post-operative level

Secondary outcomes

  1. Acute Kidney Injury

    Acute Kidney Injury as defined by KDIGO

    Time frame: Operation to Post-operative Day 7

  2. KDIGO Bundle Adherence

    Measurement of provider adherence to KDIGO components

    Time frame: Intra-operative

  3. Intra-Operative Time and Severity of Hypotension

    Intra-Operative Time and Severity (meaning how far below the threshold) where patient is in hypotension, defined as systolic blood pressure \<90 mmHg and mean arterial pressure \<65 mmHg during surgery

    Time frame: Intra-operative

  4. Total intra-operative intravenous fluid volume administered (mL)

    Provider administration of intravenous fluids during the intra-operative period, measured in milliliters (mL). Intravenous fluids include normal saline, lactated Ringer's, Plasma-Lyte, other balanced crystalloids, and colloid solutions such as albumin.

    Time frame: Intra-operative

  5. Length of Stay

    Duration of patient admission in hospital in days

    Time frame: Operation to Post-operative Day 180

  6. Intra-operative Hyperglycemic Events

    Number of intra-operative hyperglycemic events, defined as the number of recorded blood glucose measurements exceeding 180 mg/dL.

    Time frame: Intra-operative

  7. Intra-operative Nephrotoxin Exposure

    Number of nephrotoxic medications administered intra-operatively and duration of intra-operative exposure

    Time frame: Intra-operative

  8. In-Hospital Mortality

    Patient death while admitted in the hospital

    Time frame: Operation to Post-operative Day 180

  9. ICU Transfer and total time in the ICU

    Any transfers to the ICU while admitted and the total time the patient spends in the ICU

    Time frame: Postoperative

  10. Hospital Readmission

    Readmission back to a UCSF hospital following operation

    Time frame: Operation to Post-operative Day 180

  11. Dialysis Requirement

    Patients requiring dialysis following surgery

    Time frame: Operation to Post-operative Day 180

  12. Dilution Corrected KDIGO AKI measurement (Stage 1 or higher)

    Acute kidney injury (AKI) assessed using KDIGO creatinine criteria applied to dilution-corrected postoperative serum creatinine. Creatinine is corrected for hemodilution from perioperative fluid retention using the formula: Corrected Creatinine (mg/dL) = Measured Creatinine × (1 + Net Fluid Balance / Total Body Water) Where: * Net Fluid Balance (L) = Fluid inputs - urine output - blood loss - other outputs * Total Body Water (L) = 0.6 × weight (kg) for males; 0.5 × weight (kg) for females

    Time frame: AKI is defined per KDIGO as corrected creatinine increase ≥0.3 mg/dL within 48 hours or ≥1.5× baseline within 7 days. This measure captures "hidden AKI" - kidney injury masked by fluid dilution that would be missed using standard uncorrected creatinine.

  13. Total intra-operative packed red blood cells administered (units transfused)

    Provider administration of packed red blood cells during the intra-operative period, measured as total units transfused.

    Time frame: intraoperative

  14. Total intra-operative fresh frozen plasma administered (units transfused)

    Provider administration of fresh frozen plasma during the intra-operative period, measured as total units transfused.

    Time frame: intraoperative

  15. Total intra-operative platelets administered (units transfused)

    Provider administration of platelets during the intra-operative period, measured as total units transfused.

    Time frame: intraoperative

  16. Total intra-operative cryoprecipitate administered (units transfused)

    Provider administration of cryoprecipitate during the intra-operative period, measured as total units transfused.

    Time frame: intraoperative

07

Study locations

1 site
08

References and documents

Publications

  • James MT, Dixon E, Tan Z, Mathura P, Datta I, Lall RN, Landry J, Minty EP, Samis GA, Winkelaar GB, Pannu N. Stepped-Wedge Trial of Decision Support for Acute Kidney Injury on Surgical Units. Kidney Int Rep. 2024 Jul 31;9(10):2996-3005. doi: 10.1016/j.ekir.2024.07.025. eCollection 2024 Oct. PubMed 39430177 ↗
  • Zarbock A, Kullmar M, Ostermann M, Lucchese G, Baig K, Cennamo A, Rajani R, McCorkell S, Arndt C, Wulf H, Irqsusi M, Monaco F, Di Prima AL, Garcia Alvarez M, Italiano S, Miralles Bagan J, Kunst G, Nair S, L'Acqua C, Hoste E, Vandenberghe W, Honore PM, Kellum JA, Forni LG, Grieshaber P, Massoth C, Weiss R, Gerss J, Wempe C, Meersch M. Prevention of Cardiac Surgery-Associated Acute Kidney Injury by Implementing the KDIGO Guidelines in High-Risk Patients Identified by Biomarkers: The PrevAKI-Multicenter Randomized Controlled Trial. Anesth Analg. 2021 Aug 1;133(2):292-302. doi: 10.1213/ANE.0000000000005458. PubMed 33684086 ↗
  • Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract. 2012;120(4):c179-84. doi: 10.1159/000339789. Epub 2012 Aug 7. No abstract available. PubMed 22890468 ↗
  • Walsh M, Devereaux PJ, Garg AX, Kurz A, Turan A, Rodseth RN, Cywinski J, Thabane L, Sessler DI. Relationship between intraoperative mean arterial pressure and clinical outcomes after noncardiac surgery: toward an empirical definition of hypotension. Anesthesiology. 2013 Sep;119(3):507-15. doi: 10.1097/ALN.0b013e3182a10e26. PubMed 23835589 ↗
  • Sun LY, Wijeysundera DN, Tait GA, Beattie WS. Association of intraoperative hypotension with acute kidney injury after elective noncardiac surgery. Anesthesiology. 2015 Sep;123(3):515-23. doi: 10.1097/ALN.0000000000000765. PubMed 26181335 ↗
  • Kork F, Balzer F, Spies CD, Wernecke KD, Ginde AA, Jankowski J, Eltzschig HK. Minor Postoperative Increases of Creatinine Are Associated with Higher Mortality and Longer Hospital Length of Stay in Surgical Patients. Anesthesiology. 2015 Dec;123(6):1301-11. doi: 10.1097/ALN.0000000000000891. PubMed 26492475 ↗
  • Fujii T, Takakura M, Taniguchi T, Tamura T, Nishiwaki K. Intraoperative hypotension affects postoperative acute kidney injury depending on the invasiveness of abdominal surgery: A retrospective cohort study. Medicine (Baltimore). 2023 Dec 1;102(48):e36465. doi: 10.1097/MD.0000000000036465. PubMed 38050260 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Oct 2027, 12 months later.

Of 251 non-industry interventional studies with no phase under Acute Kidney Injury, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 44. This study's planned 12 months is below that.

Counting every sponsor, half of 269 studies reached it within 26 months; a quarter within 12 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2026
First posted
May 22, 2026
StartEst.
Oct 15, 2026
Primary completionEst.
Oct 15, 2027
CompletionEst.
Dec 15, 2027
Last update
May 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07604662
Responsible party
Sponsor
First posted
May 22, 2026
Start date
Oct 15, 2026 (estimated)
Primary completion
Oct 15, 2027 (estimated)
Completion
Dec 15, 2027 (estimated)
Last update
May 22, 2026

Study contacts

Andrew Bishara, MD
Contact
andrew.bishara@ucsf.edu
415-502-5880
Andrew Bishara, MD
principal investigator · University of California, San Francisco

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion